Who are BF-200 ALA 1%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rose Bengal, aminolevulinic acid (ALA), Hemoporfin PDT, 5-Methoxypsoralen, padeliporfin VTP, verteporfin, bevacizumab, triamcinolone acetonide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bf-200-ala-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BF-200 ALA 1% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BF-200 ALA 1% (BF-200 ALA 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: photosensitizer. Area: Dermatology.

phase 2 photosensitizer protoporphyrin IX (PpIX) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

BF-200 ALA 1% (BF-200 ALA 1%) — Biofrontera Bioscience GmbH. BF-200 ALA 1% is a topical photosensitizer that, when activated by light, generates reactive oxygen species to induce cell death in targeted tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BF-200 ALA 1% TARGET	BF-200 ALA 1%	Biofrontera Bioscience GmbH	phase 2	photosensitizer	protoporphyrin IX (PpIX)
Rose Bengal	Rose Bengal	University of California, San Francisco	marketed	Photosensitizer
aminolevulinic acid (ALA)	aminolevulinic acid (ALA)	University of California, Davis	marketed	Photosensitizer	Protoporphyrin IX (endogenous photosensitizer generated from ALA)
Hemoporfin PDT	Hemoporfin PDT	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	marketed	Photosensitizer	Porphyrin-based photosensitizer (non-receptor mediated)
5-Methoxypsoralen	5-Methoxypsoralen	Medical University of Vienna	phase 3	Furocoumarin photosensitizer	DNA (intercalating agent)
padeliporfin VTP	padeliporfin VTP	Steba Biotech S.A.	phase 3	Photosensitizer
verteporfin, bevacizumab, triamcinolone acetonide	verteporfin, bevacizumab, triamcinolone acetonide	Shahid Beheshti University of Medical Sciences	phase 3	photosensitizer, monoclonal antibody, corticosteroid	VEGF-A, VEGF receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (photosensitizer class)

Biofrontera Bioscience GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BF-200 ALA 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/bf-200-ala-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing